Will See Growth From Newly Launched Medicines in 2019, Says Roche’s CEO

The video discusses the company's successful 2018 results driven by new medicines and anticipates continued growth in 2019. The focus is on innovation and defending intellectual property against biosimilar competition. The impact of US healthcare policies on pricing is explored, emphasizing the importance of innovation. The company's M&A strategy remains opportunistic, with interest in neuroscience and oncology. Finally, the relationship with Novartis and its stake in the company is addressed.

What is the company's stance on mergers and acquisitions?

What emerging disease areas is the company excited about for future growth?